Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial.

Scheiman JM, Herlitz J, Veldhuyzen van Zanten SJ, Lanas A, Agewall S, Nauclér EC, Svedberg LE, Nagy P.

J Cardiovasc Pharmacol. 2013 Mar;61(3):250-7. doi: 10.1097/FJC.0b013e31827cb626.

PMID:
23188121
2.

Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors.

Hawkey C, Talley NJ, Yeomans ND, Jones R, Sung JJ, Långström G, Naesdal J, Scheiman JM; NASA1 SPACE1 Study Group..

Am J Gastroenterol. 2005 May;100(5):1028-36.

PMID:
15842575
3.

Burden of upper gastrointestinal symptoms in patients receiving low-dose acetylsalicylic acid for cardiovascular risk management: a prospective observational study.

Bytzer P, Pratt S, Elkin E, Næsdal J, Sörstadius E.

Am J Cardiovasc Drugs. 2013 Feb;13(1):27-35. doi: 10.1007/s40256-012-0001-4.

PMID:
23315343
4.

Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events.

Sylvester KW, Cheng JW, Mehra MR.

Vasc Health Risk Manag. 2013;9:245-54. doi: 10.2147/VHRM.S44265. Epub 2013 May 16. Review.

5.

Impact of gastrointestinal problems on adherence to low-dose acetylsalicylic Acid: a quantitative study in patients with cardiovascular risk.

Moberg C, Naesdal J, Svedberg LE, Duchateau D, Harte N.

Patient. 2011;4(2):103-13. doi: 10.2165/11589200-000000000-00000.

PMID:
21766899
6.

Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin.

Yeomans N, Lanas A, Labenz J, van Zanten SV, van Rensburg C, Rácz I, Tchernev K, Karamanolis D, Roda E, Hawkey C, Nauclér E, Svedberg LE.

Am J Gastroenterol. 2008 Oct;103(10):2465-73. doi: 10.1111/j.1572-0241.2008.01995.x. Epub 2008 Jul 12.

PMID:
18637091
7.

Esomeprazole for the management of upper gastrointestinal symptoms in patients who require NSAIDs: a review of the NASA and SPACE double-blind, placebo-controlled studies.

Hawkey CJ, Svedberg LE, Naesdal J, Byrne C.

Clin Drug Investig. 2009;29(10):677-87. doi: 10.2165/11317830-000000000-00000.

PMID:
19715384
8.

Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.

Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, Hui AJ, Wu JC, Leung WK, Lee VW, Lee KK, Lee YT, Lau JY, To KF, Chan HL, Chung SC, Sung JJ.

N Engl J Med. 2005 Jan 20;352(3):238-44.

9.

The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk.

Pratt S, Thompson VJ, Elkin EP, Næsdal J, Sörstadius E.

Am J Cardiovasc Drugs. 2010;10(5):281-8. doi: 10.2165/11584410-000000000-00000.

PMID:
20666569
10.

The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.

Arber N, Lieberman D, Wang TC, Zhang R, Sands GH, Bertagnolli MM, Hawk ET, Eagle C, Coindreau J, Zauber A, Lanas A, Levin B.

Clin Ther. 2012 Mar;34(3):569-79. doi: 10.1016/j.clinthera.2012.02.001. Epub 2012 Mar 2.

PMID:
22386831
11.

Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study.

Sugano K, Choi MG, Lin JT, Goto S, Okada Y, Kinoshita Y, Miwa H, Chiang CE, Chiba T, Hori M, Fukushima Y, Kim HS, Chang CY, Date M; LAVENDER Study Group..

Gut. 2014 Jul;63(7):1061-8. doi: 10.1136/gutjnl-2013-304722. Epub 2013 Dec 10.

PMID:
24326741
12.

Acetylsalicylic acid/esomeprazole fixed-dose combination.

Burness CB, Scott LJ.

Drugs Aging. 2012 Mar 1;29(3):233-242. doi: 10.2165/11208610-000000000-00000. Review.

PMID:
22372726
13.

Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment.

Lanas A, Scheiman J.

Curr Med Res Opin. 2007 Jan;23(1):163-73. Review.

PMID:
17257477
14.

Tegaserod for dyspepsia and reflux symptoms in patients with chronic constipation: an exploratory open-label study.

Zeng J, Zuo XL, Li YQ, Wei W, Lv GP.

Eur J Clin Pharmacol. 2007 Jun;63(6):529-36. Epub 2007 Mar 20.

PMID:
17468863
15.

Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON).

Scheiman JM, Devereaux PJ, Herlitz J, Katelaris PH, Lanas A, Veldhuyzen van Zanten S, Nauclér E, Svedberg LE.

Heart. 2011 May;97(10):797-802. doi: 10.1136/hrt.2010.217547. Epub 2011 Mar 17.

16.
17.

Esomeprazole alone compared with esomeprazole plus aspirin for the treatment of aspirin-related peptic ulcers.

Liu CP, Chen WC, Lai KH, Mar GY, Lin SY, Ger LP, Hsu PI; Formosa Acid-Related Disease (FARD) Study Group..

Am J Gastroenterol. 2012 Jul;107(7):1022-9. doi: 10.1038/ajg.2012.87. Epub 2012 Apr 17.

PMID:
22508148
18.

Epidemiology of Upper Gastrointestinal Damage Associated with Low-Dose Aspirin.

Hsu PI, Tsai TJ.

Curr Pharm Des. 2015;21(35):5049-55.

PMID:
26369688
19.

Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications.

Lai KC, Chu KM, Hui WM, Wong BC, Hung WK, Loo CK, Hu WH, Chan AO, Kwok KF, Fung TT, Wong J, Lam SK.

Clin Gastroenterol Hepatol. 2006 Jul;4(7):860-5. Epub 2006 Jun 22.

PMID:
16797240
20.

Strategies to reduce the GI risks of antiplatelet therapy.

Scheiman JM.

Rev Cardiovasc Med. 2005;6 Suppl 4:S23-31. Review.

PMID:
17710073

Supplemental Content

Support Center